Related references
Note: Only part of the references are listed.The biological and clinical importance of epithelial-mesenchymal transition in circulating tumor cells
Huiying Liu et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2015)
Circulating tumour cells-a bona fide cause of metastatic cancer
N. J. Caixeiro et al.
CANCER AND METASTASIS REVIEWS (2014)
EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer
Axel Heidenreich et al.
EUROPEAN UROLOGY (2014)
New frontiers in circulating tumor cell analysis: A reference guide for biomolecular profiling toward translational clinical use
Therese M. Becker et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Circulating tumor cell detection in high-risk non-metastatic prostate cancer
Jasmin Loh et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2014)
Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer
Amir Goldkorn et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
The current role and limitations of surrogate endpoints in advanced prostate cancer
Leonard G. Gomella et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2014)
Comparison of circulating tumor cells (CTC) in peripheral blood and disseminated tumor cells in the bone marrow (DTC-BM) of breast cancer patients
Christian Schindlbeck et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2013)
Detection of circulating tumor cells in different stages of prostate cancer
Mark Thalgott et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2013)
Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures
Xuan Huang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2012)
Interpretation of Changes in Circulating Tumor Cell Counts
Frank A. W. Coumans et al.
TRANSLATIONAL ONCOLOGY (2012)
The Potential of Circulating Tumor Cells as a Liquid Biopsy to Guide Therapy in Prostate Cancer
Klaus Pantel et al.
CANCER DISCOVERY (2012)
Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer
Michael Rink et al.
BJU INTERNATIONAL (2011)
Comparison of Circulating MicroRNA 141 to Circulating Tumor Cells, Lactate Dehydrogenase, and Prostate-Specific Antigen for Determining Treatment Response in Patients With Metastatic Prostate Cancer
Jason C. Gonzales et al.
CLINICAL GENITOURINARY CANCER (2011)
Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance
Yun-Fan Sun et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2011)
Increases in Quantitative D-Dimer Levels Correlate With Progressive Disease Better Than Circulating Tumor Cell Counts in Patients With Refractory Prostate Cancer
Joseph D. Khoury et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2010)
Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel
M. H. Strijbos et al.
EUROPEAN JOURNAL OF CANCER (2010)
Imaging Studies in Metastatic Urogenital Cancer Patients Undergoing Systemic Therapy: Recommendations of a Multidisciplinary Consensus Meeting of the Association of Urological Oncology of the German Cancer Society
Axel Heidenreich et al.
UROLOGIA INTERNATIONALIS (2010)
Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience
D. Olmos et al.
ANNALS OF ONCOLOGY (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Prognostic Significance of Circulating Tumor Cells in Patients With Hormone Refractory Prostate Cancer
Takatsugu Okegawa et al.
JOURNAL OF UROLOGY (2009)
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data
Howard I. Scher et al.
LANCET ONCOLOGY (2009)
Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: Relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study
Dominik R. Berthold et al.
CLINICAL CANCER RESEARCH (2008)
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
Johann S. de Bono et al.
CLINICAL CANCER RESEARCH (2008)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer
Takatsugu Okegawa et al.
JOURNAL OF UROLOGY (2008)
Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials
Mark T. Fleming et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
Circulating tumor cells versus imaging - Predicting overall survival in metastatic breast cancer
G. Thomas Budd et al.
CLINICAL CANCER RESEARCH (2006)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
